flecainide has been researched along with Amyotrophic Lateral Sclerosis in 1 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Flecainide-treated patients maintained stabilized peripheral axonal excitability over the study compared to placebo." | 6.80 | Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. ( Cheah, BC; Kiernan, MC; Kirby, A; Lin, CS; Mann, KP; Park, SB; Vucic, S; Winhammar, J; Zoing, MC, 2015) |
| "Flecainide-treated patients maintained stabilized peripheral axonal excitability over the study compared to placebo." | 2.80 | Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. ( Cheah, BC; Kiernan, MC; Kirby, A; Lin, CS; Mann, KP; Park, SB; Vucic, S; Winhammar, J; Zoing, MC, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, SB | 1 |
| Vucic, S | 1 |
| Cheah, BC | 1 |
| Lin, CS | 1 |
| Kirby, A | 1 |
| Mann, KP | 1 |
| Zoing, MC | 1 |
| Winhammar, J | 1 |
| Kiernan, MC | 1 |
1 trial available for flecainide and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial.
Topics: Adult; Amyotrophic Lateral Sclerosis; Female; Flecainide; Humans; Male; Middle Aged; Neuroprotective | 2015 |